Summary.-The sera of 80 newly diagnosed lung-cancer patients have been examined for immune complexes and autoantibodies. Control subjects consisted of 20 bronchitic patients and 150 normal blood donors. Immune-complex measurements used 4 established and sensitive techniques (Raji cell assay, fluid and solid-phase Clq assays and conglutinin-binding assay) and a 5th newly devised technique based on the binding of polyethylene-glycol-precipitated immune-complex-rich serum fractions to Staphylococcus aureus. Using the Raji cell assay and the S. aureus binding assay to measure immune complexes, both newly diagnosed lung cancer patients and bronchitic patients had significantly higher prevalences of immune complexes than normal controls, but the two groups of patients did not differ significantlv in either prevalence or quantity of immune complexes. When techniques which depend solely upon complement fixation (Clq assays and conglutinin binding) were used, only meagre quantities of immune complexes were found, and in at most 15% of newly diagnosed lung-cancer patients. The presence of autoantibodies in newly diagnosed cancer patients and controls appeared to correlate with the increase in the detectable prevalence of immune complexes.
THE PRESENCE of circulating immune complexes in a variety of human disorders, notably the idiopathic inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis, is now well established. In some human malignant diseases, agents of the kind originally described as "blocking factors" by the Hellstroms more than a decade ago (Hellstrom et al., 1969) have since been recognized as complexes of antigens and antibodies (Sjogren et al., 1971; Hellstrom et al., 1977) . With the advent of better techniques for their detection, apparently successful efforts have been made to find immune complexes in various human malignancies (Theofilopoulos et al., 1977; Lambert et al., 1978; Baldwin et al., 1979) . However, since the existing assays for immune complexes are antigenically non-* Present address: MRC Clinical and Population Road, Edinburgh. specific, it may be expected that not all the immune complexes so far detected in malignant disease will be found to contain tumour-related antigens. In this paper are described studies of immune complexes in the sera of a large group of patients with lung cancer, examined near to the time of clinical presentation of the disease and before the start of treatment. Of the 18 methods subjected to a recent international study (Lambert et al., 1978) 4 of the more sensitive (the Raji cell radioimmunoassay, the fluid phase and solid phase Clq assays and the conglutinin-binding test) have been used to detect immune complexes. In addition, a newly devised technique based on the binding of immune complexes to Staphylococcus aureus has been used.
The significance attached to immune
Cytogenetics Unit Western General Hospital, Crewe complexes in cancer relates to the concepts, expressed in earlier studies (Hellstrom et al., 1969; Sjogren et al., 1971 ) that immune complexes may have unfavourable influences upon the immunity of tumour-bearing hosts. The implication of these concepts is that such complexes may comprise anti-tumour antibodies and tumour-cell antigens.
MATERIALS AND METHODS

Subjects
Sera were obtained from 80 lung-cancer patients at the City Hospital, Edinburgh. All were studied before the start of treatment and only those patients with a subsequently confirmed diagnosis of bronchogenic carcinoma were included. Normal control sera were obtained from 150 randomly selected blood donors. Sera were also obtained from 20 bronchitic patients to serve as benign chestdisease controls of comparable age to the cancer patients, and from patients with either rheumatoid arthritis or insulin-dependent diabetes to serve as positive controls for immune-complex assays. Sera were collected only from bronchitic patients clinically judged not to be suffering from infection at that time. Sera were stored in aliquots at -40°C. The age range of the lung-cancer patients was 47-84 years, of the bronchitic patients 50-82 years, and of the normal blood donors 18-58 years.
Immunological reagents
Protein A (Pharmacia) was radiolabelled to a sp. act. of 20 /tCi/,ug by an adaptation of the chloramine-T method (Dorval et al., 1975) . Human Clq was purified by the method of Yonemasu & Stroud (1971) and radiolabelled to a sp. act. of 1 ,Ci/,ug, using lactoperoxidase (Heusser et al., 1973) . Bovine conglutinin was purified by absorption to yeast (Lachmann, 1967) and further purified by DEAE-A50 chromatography. Standard preparations of aggregated Ig were tested whenever immunecomplex assays were performed. Cohn Fraction II Ig was ultracentrifuged at 100,000 g and aggregated by heating at 63°C for 20 min. Standard preparations were made by diluting aggregated Ig from 1 mg/ml in serial doubling dilutions in normal human serum to 1-2 '4g/ml. 20 jug/ml, so 21 ,ug/ml was taken as the lower limit of positivity. This modification of RAJI has been used successfully in other studies (Irvine et al., 1978a) .
Solid-phase Clq assay (Clq-SP).-The technique of Svehag (1975) adapted by Hay et al. (1977) was used with 1251-protein A (2-5 ng; 5 x 104 ct/min). Results were expressed as percentage Protein A bound, and those results exceeding the 90th percentile of normal blood-donor control values were considered positive.
Fluid-phase Clq assay (Clq-FP). The test described by Zubler et al. (1976) with EDTA treatment of sera was used without modification. Those percentage Clq-binding values found to exceed the mean + 2 s.d. of the mean of normal controls were considered positive.
Conglutinin -binding test (Kg -B). -The assay described by Casali et al. (1977) was used with 1251-protein A (5 ng; 105 ct/min). Results were expressed as ,g/ml of aggregated Ig equivalents, by reference to standard preparations of aggregated Ig. Those results which exceeded the 90th percentile of normal control subjects were considered positive.
Staphylococcus aureus binding test (STAB). -This is a newly devised assay, details of which are to be reported elsewhere (Barkas, 1980) . Briefly, 100 ,u of each serum was treated with EDTA and 2 ml of 6% polyethylene glycol 6000 (PEG) in borate-saline buffer (pH 8.4) was added. After overnight incubation at 4°C, precipitates were recovered by centrifugation, washed in 5 % PEG and redissolved in phosphate-buffered saline (PBS) pH 7-2. To duplicate lOO,ul aliquots of resuspended material was added 100 jul of a 1% suspension of heat-killed and formalinfixed S. aureus suspension in PBS plus 0.5% bovine serum albumin. After incubation at 37°C for 1 h the staphylococci were washed twice and 30 ng of 1251-Protein A was added to each tube. After 30min incubation at 4°C the staphyloccoci were washed twice and the amounts of 1251-Protein A bound were-determined. Results Autoantibodies.-Standard immunofluorescence techniques with anti-human IgG and sections of rat tissues were used, except for thyroid autoantibodies, when human thyroid sections were used. Conventional tanned-redcell tests with thyroglobulin and thyroid microsomal antigens were also used. All tests for autoantibodies were performed by individuals without knowledge of the identity of the sera or of the results of immune-complex assays.
RESULTS
Immune-complex measurements in newly diagnosed lung-cancer patients and controls
Initially, sera from newly diagnosed patients were tested by RAJI and Clq techniques. Different immune-complex assays preferentially detect subspecies of immune complexes which are defined by characteristics of the complex such as Ig class and subclass, antigen valency, complex size and the ability of the complex to activate the complement system (WHO Technical Report Series, 1977) . The parallel use of two or more immune complex assays may help to avdid such methodological restrictions.
Raji cell radioimmunoassay.-Considerable overlap among the values obtained for patients and controls was apparent in the results, but 18/41 sera from lungcancer patients (44%, P < 0*05, Fisher's test) and 50% of 16 sera from bronchitic patients (P < 0-05) gave values above 20 ,ug/ml in comparison with 23-5% (16) of 68 normal blood donors (Fig. 1 ). There were no significant differences between the values for positive lung cancer and bronchitis sera (Mann-Whitney test) or between the prevalences of immune complexes in these patients (Fisher's test).
Fluid-phase Clq binding.-Of 80 lungcancer sera, 12 gave Clq binding above normal control levels (15%, P < 0-05 from x2) and 1 of 18 bronchitis sera was positive (6%, not significant) (Fig. 2) in cancer and 60% in bronchitis.
Solid-phase Clq binding. There were no significant differences among the prevalences of immune complexes detected in lung cancer (1 30o), bronchitis (6%) or in the sera of 80 normal blood donors (10%).
Of 54 cancer sera tested by 51 were also tested by Clq-FP, and 84% of the results were in agreement. The results were totally in accord for 15 bronchitis sera tested in both assays. Of the 10 rheumatoid-arthritis sera tested also by Clq-FP, 5 were positive. These results for rheumatoid arthritis agree with results of more extensive studies (Lambert et al., 1978) and indicate that, of the Clq binding tests, the fluid-phase test is more sensitive than the solid-phase test in rheumatoid arthritis.
Because of the apparently different prevalences of immune complexes detectable in lung-cancer sera by RAJI and Clq binding tests, confirmation of the prevalence of complement-binding immune complexes was sought in the conglutinin-binding (Kg-B) test. The bovine protein conglutinin has a high affinity for C3bi. The characteristics of artificially formed immune complexes which facilitate their detection by RAJI and Kg-B appear to be similar (Casali et al., 1977) .
Conglutinin binding test. There was no evidence of conglutinin-binding iinmune complexes in sera from newly diagnosed lung-cancer patients. Only 3/75 tested gave any detectable Kg-B values and these (5-10 ,ug/ml) fell below the 90th percentile (17 ,ug/ml) of the normal control group. Of 103 normal blood donor sera tested, about 100% gave clearly positive values and these sera were also positive by RAJI. Of 14 sera from insulin-treated diabetics included as positive controls, 12 gave Kg-B binding between 3 and 215 ,ug/ml and 5 of these sera fell above the 90th percentile of normal control values (P<0.02, x2 test). patients, and also in the sera of blooddonor controls (Table) . The latter group was selected to include a number of RAJIpositive sera. When the prevalence of immune complexes detectable by RAJI was compared with the presence of autoantibodies in the sera, similar trends emerged for all 3 groups of subjects. The sera of subjects found positive for autoantibodies had considerably higher prevalences of immune complexes than those found negative for autoantibodies (Fig. 4) Immune complexes were also found in patients with benign chest disease at prevalences not dissimilar from those for lung cancer. In both bronchitic and lungcancer patients, infection may contribute to the formation of serum immune complexes, though bronchitic patients with clinical infection at the time of study were excluded. In all subjects, including normals, the increase in autoimmune phenomena which accompanies ageing (Irvine et al., 1970; Burnet, 1974) Jansen et al. (1977) .
A surprising aspect of this and other studies (Schrohenloher et al., 1.978 ) is the apparent lack of correlation among the results of immune-complex assays used in investigations of lung-cancer patients. In studies of immune complexes in other diseases, satisfactory correlations between assays have been shown (Lambert et al., 1978; Irvine et al., 1978b) . The reasons for such disparity no doubt involve differences in methodology, but may also reflect possible heterogeneity of immune complexes in lung cancer. Such possible heterogeneity complicates the interpretation of immune-complex results from existing assay procedures, and clearly necessitates the development of tumourantigen-specific methods.
There is no clear evidence yet that immune complexes in lung cancer contain unique tumour antigens, though recurrence of tumour growth and immune complexes appear to correlate in the studies of Rossen et al. (1977) . Surgical removal of tumour is associated with a reduction in polymorphonuclear leucocyte inclusions (Jansen et al., 1977) , implying a decline in immune-complex levels. However, these results do not necessarily imply tumour specificity of the immune complexes, in view of the diversity in immune complexes found by different techniques and their association with autoantibodies. In preliminary experiments (Guy & James, unpublished) using gel-filtration chromatography and polyacrylamide-gel electrophoresis, we have been unable to find components of immune complexes which are unique to the sera of lung-cancer patients.
A fundamental problem, relevant to tumour immunology in general and to lung cancer in particular, is the possible biological significance of tumour antigens. Thus, although a number of onco-foetal antigens have been found to be associated with lung cancer (Lo Gerfo, 1976 ) their specificity and immunogenicity remain in doubt. The specificity of antigens found in immune complexes in the sera of lungcancer patients is therefore of obvious importance and as yet unresolved. 
